Impact of hereditary thrombophilia on cancer-associated thrombosis, tumour susceptibility and progression: A review of existing evidence

• Type: Another Publication in an International Scientific Journal
• Date: 2022

Authors

Tavares, V (Author) Other; Neto, BV (Author) Other; Vilas-Boas, MI (Author) Other; Pereira, D (Author) Other; Rui Medeiros (Author) ICBAS

Journal

Title: Biochimica et Biophysica Acta - Reviews on Cancer

Vol. 1877

ISSN: 0304-419X

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 10 Citations

Scopus - 12 Citations

Other information

Authenticus ID: P-00X-402

DOI: 10.1016/j.bbcan.2022.188778

Abstract (EN): Venous thromboembolism (VTE) is a cardiovascular disorder frequently diagnosed among cancer patients. Aside from being common, VTE severely deteriorates the prognosis of these patients as they face a higher risk of morbidity and mortality, which makes clinical tools able to identify the patients more prompt to thrombogenesis very attractive. Over the years, several genetic polymorphisms have been linked with VTE susceptibility in the general population. However, their clinical usefulness as predictive biomarkers for cancer-related VTE is yet unclear. Furthermore, as a two-way association between cancer and VTE is well-recognized, with haemostatic components fuelling tumour progression, haemostatic gene polymorphisms constitute potential cancer predictive and/or prognostic biomarkers as well. Thus, in this article, we review the existing evidence on the role of these polymorphisms on cancer-related VTE and their impact on cancer onset and progression. Despite the promising findings, the existing studies had inconsistent results most likely due to their limited statistical power and population heterogeneity. Future studies are therefore required to clarify the role of these polymorphisms in setting of malignancy.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 11